Does Fallon Community Health Plan (FCHP) Cover Vyvanse?

How FCHP Handles Vyvanse on Its Formulary

Fallon Community Health Plan, a Massachusetts-based health plan now operating under the Fallon Health umbrella, maintains a tiered formulary that categorizes medications by cost and clinical preference. Vyvanse (lisdexamfetamine dimesylate) appears on most FCHP commercial and MassHealth-affiliated formularies but is not classified as a preferred brand.

FCHP uses a four-to-five tier structure common across New England health plans. Generic medications occupy Tier 1, preferred brands sit on Tier 2, and non-preferred brands land on Tier 3 or higher. Brand-name Vyvanse typically falls on Tier 3, which carries higher cost-sharing than preferred alternatives like generic amphetamine mixed salts. The FDA's prescribing information for Vyvanse confirms two approved indications: attention-deficit/hyperactivity disorder in patients aged 6 and older, and moderate-to-severe binge eating disorder in adults [1]. FCHP's coverage criteria map directly to these FDA-approved uses.

Since generic lisdexamfetamine became available in August 2023 following patent expiration, FCHP has begun placing the generic version on a lower formulary tier for many plan designs. This shift mirrors industry-wide trends. A 2024 analysis published in JAMA Network Open found that generic entry for branded ADHD medications reduced average out-of-pocket costs by 40% to 60% within the first year of availability [2]. Members should verify their specific plan's formulary on the FCHP member portal or by calling the number on the back of their insurance card, since tier placement varies across plan types (HMO, PPO, MassHealth ACO).

Prior Authorization and Step Therapy Requirements

FCHP requires prior authorization for Vyvanse. This is standard practice. The requirement exists because the plan prefers that prescribers start with less expensive, clinically equivalent stimulant medications before moving to branded or higher-cost options.

Step therapy protocols at FCHP typically mandate a documented trial of at least one generic first-line stimulant. The most common required first steps include generic mixed amphetamine salts (the generic form of Adderall or Adderall XR) and generic methylphenidate formulations (generic Concerta or Ritalin). According to the American Academy of Pediatrics 2019 clinical practice guideline for ADHD, both amphetamine-based and methylphenidate-based stimulants carry Grade A evidence for efficacy in children aged 6 and older [3]. The guideline does not preferentially rank one stimulant class over another, which supports the clinical rationale behind step therapy.

To satisfy prior authorization, prescribers generally must document the following: a confirmed ADHD or binge eating disorder diagnosis using DSM-5 criteria, a trial of at least one preferred generic stimulant lasting a minimum of 4 to 6 weeks at adequate doses, and a documented reason for treatment failure (inadequate response, intolerable side effects, or a clinical contraindication to the preferred agent). Processing takes 24 to 72 hours for standard requests. Urgent requests tied to a clinical need can be expedited to within 24 hours.

If the prior authorization is denied, members have the right to appeal. FCHP follows Massachusetts Division of Insurance regulations requiring a two-level internal appeal process and access to an external independent review [4].

How Vyvanse Differs from Other Covered ADHD Medications

Vyvanse is a prodrug. The body converts lisdexamfetamine into dextroamphetamine only after oral ingestion and enzymatic hydrolysis in the blood. This prodrug mechanism creates a smoother pharmacokinetic profile with a gradual onset and a duration of action lasting approximately 10 to 14 hours in most patients [1].

This pharmacokinetic property distinguishes Vyvanse from immediate-release stimulants and even some extended-release formulations. A 2013 randomized controlled trial published in the Journal of the American Academy of Child and Adolescent Psychiatry (N=314) compared lisdexamfetamine with extended-release mixed amphetamine salts and found comparable efficacy on the ADHD Rating Scale IV, with lisdexamfetamine showing a slightly longer duration of symptom control into the evening hours [5]. The clinical relevance of that difference varies by patient. Some individuals need full-day coverage through homework hours or evening responsibilities, making Vyvanse's extended profile valuable.

FCHP's formulary includes several alternative ADHD medications at lower tiers:

• Generic mixed amphetamine salts XR (Tier 1 or 2): 12-hour duration, widely available
• Generic methylphenidate ER (Tier 1 or 2): multiple formulations with 8 to 12-hour coverage
• Generic atomoxetine (Tier 1 or 2): non-stimulant option, no abuse potential, slower onset of full effect (4 to 6 weeks)
• Guanfacine ER (Tier 2): non-stimulant, commonly used adjunctively or in patients who cannot tolerate stimulants

The choice between Vyvanse and these alternatives is a clinical decision that should account for individual response patterns, side effect profiles, duration-of-action needs, and abuse risk considerations. Lisdexamfetamine's prodrug design confers a lower abuse liability compared to immediate-release dextroamphetamine, as confirmed by a human abuse potential study published in Clinical Drug Investigation [6].

Cost Breakdown: What FCHP Members Actually Pay

Out-of-pocket costs for Vyvanse under FCHP depend on the specific plan, formulary tier, and whether the member fills the brand or generic version. Actual numbers vary, but general ranges based on FCHP's published plan structures provide a useful estimate.

For brand-name Vyvanse at Tier 3, members on commercial HMO plans can expect copays ranging from $50 to $150 per 30-day supply. Some high-deductible health plans (HDHPs) require members to meet the full deductible before the plan shares cost, meaning the first several fills could cost the full retail price (approximately $350 to $450 without discount programs). Generic lisdexamfetamine, when placed on Tier 1 or 2, typically carries copays of $15 to $75.

Takeda, the manufacturer of brand Vyvanse, continues to offer a copay savings card for commercially insured patients. The program can reduce out-of-pocket costs to as low as $30 per month, with a maximum annual benefit. This card does not apply to government-funded insurance (MassHealth, Medicare Part D, Tricare). Members enrolled in FCHP's MassHealth ACO plans should check whether their specific MassHealth formulary covers generic lisdexamfetamine at a $0 to $3.65 copay, which is the standard MassHealth pharmacy copay structure [4].

Mail-order pharmacy options through FCHP's preferred pharmacy benefit manager may offer a 90-day supply at a lower per-unit cost. This can reduce the annual expense by 10% to 20% compared to monthly retail fills.

FCHP Coverage for Vyvanse in Binge Eating Disorder

Vyvanse holds FDA approval for moderate-to-severe binge eating disorder (BED) in adults, the only stimulant medication with this specific indication [1]. FCHP covers Vyvanse for BED, but the prior authorization criteria differ slightly from ADHD coverage.

For BED, FCHP typically requires documentation that the patient meets DSM-5 diagnostic criteria for moderate-to-severe BED (defined as a minimum of 3 binge episodes per week for at least 3 months). The prescriber may also need to document that non-pharmacological interventions (cognitive behavioral therapy, structured dietary counseling) were considered or attempted. The key trials supporting this indication (two Phase 3 studies, N=724 combined) demonstrated that lisdexamfetamine 50 mg and 70 mg significantly reduced binge eating days per week compared to placebo, with a mean reduction of approximately 3.87 days per week versus 2.51 days for placebo at 12 weeks [7].

Step therapy for BED does not apply in the same way as ADHD. There are no generic stimulant alternatives approved for BED. FCHP may still require prior authorization to confirm the diagnosis and clinical appropriateness, but the step-through requirement for a cheaper stimulant generally does not apply here. This distinction is worth raising with your prescriber if you are seeking Vyvanse specifically for binge eating disorder.

How to Get Vyvanse Approved Through FCHP

Getting Vyvanse covered involves a sequence of steps. Your prescriber handles most of the process, but knowing the workflow helps you avoid delays.

Step 1: Confirm your formulary. Log into the FCHP member portal or call member services to verify Vyvanse's tier and prior authorization requirements on your specific plan. Formulary details change at least annually (and sometimes mid-year for employer-sponsored plans).

Step 2: Complete step therapy if required. If your plan mandates a trial of a generic stimulant first, work with your prescriber to document the trial duration, dose, and reason for discontinuation. Prescribers should note whether the issue was lack of efficacy, side effects (e.g., insomnia, appetite suppression, rebound irritability), or a specific contraindication.

Step 3: Submit prior authorization. Your prescriber's office submits the prior authorization electronically through the FCHP pharmacy benefit portal. Include diagnosis codes (F90.0/F90.1/F90.2 for ADHD, F50.81 for BED), documentation of step therapy completion, and clinical justification.

Step 4: Appeal if denied. First-level appeals go to FCHP's pharmacy team. A peer-to-peer review (prescriber-to-FCHP medical director) can sometimes resolve denials faster than the written appeal process. Second-level appeals and external review through the Massachusetts Office of Patient Protection are available if the first appeal fails.

A 2022 study in Health Affairs found that 75% of prior authorization denials for ADHD medications were overturned on first appeal when supported by adequate clinical documentation [8]. Thorough documentation at the initial submission stage reduces the chance of denial.

MassHealth and Medicare Considerations for FCHP Members

FCHP serves a large MassHealth population through its MassHealth ACO and Senior Care Options plans. Coverage rules differ substantially for government-funded plan types.

MassHealth covers generic lisdexamfetamine under its preferred drug list, typically at minimal or no copay ($0 to $3.65 depending on the member's eligibility category). Brand Vyvanse requires prior authorization through MassHealth's Drug Utilization Review program. The MassHealth formulary follows its own step therapy protocols, which may differ from FCHP's commercial formulary [4].

For FCHP Medicare Advantage and Senior Care Options members, Vyvanse coverage falls under the Medicare Part D pharmacy benefit. The Centers for Medicare and Medicaid Services (CMS) require Part D plans to cover "all or substantially all" drugs in six protected classes. ADHD stimulants are not in these protected classes, so FCHP's Medicare plans have discretion over tier placement and utilization management. The CMS Medicare Plan Finder allows members to search their specific FCHP Medicare plan formulary [9].

Adults over 65 prescribed stimulants may also face additional clinical review. The American Geriatrics Society Beers Criteria identifies amphetamine-based stimulants as potentially inappropriate in older adults due to cardiovascular risk, though this is a clinical guideline, not an automatic coverage exclusion [10]. Prescribers should document cardiovascular risk assessment (blood pressure, heart rate, ECG if indicated) when requesting stimulant authorization for older adults.

Pharmacy Network and Fill Options

FCHP contracts with a pharmacy network that includes major retail chains (CVS, Walgreens, Walmart) and independent pharmacies across Massachusetts and parts of adjacent states. Filling Vyvanse at an in-network pharmacy is required to receive plan-rate pricing.

Members using specialty or mail-order pharmacy channels can often secure a 90-day supply, which reduces both the per-fill copay (many plans charge 2.5x the 30-day copay for a 90-day supply rather than 3x) and the number of prior authorization renewals needed per year. FCHP's preferred mail-order pharmacy information is available on the member portal.

Schedule II controlled substances like Vyvanse are subject to Massachusetts Board of Registration in Pharmacy regulations. Electronic prescribing (EPCS) is mandated for Schedule II drugs in Massachusetts. Paper prescriptions are no longer accepted for Vyvanse at most pharmacies. Prescriptions are valid for 30 days from the date written and cannot include refills. Each 30-day supply requires a new prescription, though prescribers can issue up to three sequential 30-day prescriptions at one visit [11].

Generic Lisdexamfetamine: The Cost-Effective Alternative

Since Takeda's Vyvanse patent expired and generic lisdexamfetamine dimesylate entered the market in August 2023, the cost picture has shifted substantially. Multiple manufacturers now produce generic versions, and FCHP has responded by placing generics on lower formulary tiers for most plan designs.

Generic lisdexamfetamine is rated AB by the FDA, meaning it is considered therapeutically equivalent to brand Vyvanse. The FDA Orange Book confirms bioequivalence through standard pharmacokinetic studies [12]. Patients switching from brand to generic should not expect a difference in efficacy or side effect profile, though individual variation in inactive ingredients (fillers, dyes) can occasionally affect tolerability.

If FCHP's prior authorization or step therapy requirements are causing delays, asking the prescriber to write for generic lisdexamfetamine instead of brand Vyvanse may bypass some restrictions. Some FCHP plans exempt preferred generics from prior authorization altogether, allowing immediate fill at Tier 1 copay rates. Confirm this with FCHP member services before assuming the generic is exempt.

The average wholesale price for generic lisdexamfetamine has dropped approximately 55% to 70% below brand Vyvanse pricing since the first year of generic availability, according to data from the FDA's National Drug Code Directory [12]. This pricing pressure benefits both the plan and the member.